| Zacks Company Profile for Trevena, Inc. (TRVN : OTC) |
|
|
| |
| • Company Description |
| Trevena, Inc. is a biopharmaceutical company. It focuses on discovering and developing therapeutics for G protein coupled receptors. The Company's product pipeline includes TRV027, TRV130, TRV734 and Delta opioid biased ligand which are in different clinical phases. Trevena, Inc. is based in King of Prussia, Pennsylvania.
Number of Employees: 23 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.99 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,404 shares |
| Shares Outstanding: 0.96 (millions) |
| Market Capitalization: $0.95 (millions) |
| Beta: 0.61 |
| 52 Week High: $7.85 |
| 52 Week Low: $0.17 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-2.02% |
-5.69% |
| 12 Week |
-11.64% |
-25.68% |
| Year To Date |
-34.03% |
-38.22% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
955 Chesterbrook Boulevard Suite 110
-
Chesterbrook,PA 19087
USA |
ph: 610-354-8840
fax: - |
ir@trevena.com |
http://www.trevena.com |
|
|
| |
| • General Corporate Information |
Officers
Carrie L. Bourdow - Chief Executive Officer;Chair of the Board of Dire
Barry Shin - Executive Vice President; Chief Operating Officer
Scott Braunstein - Director
Mark Corrigan - Director
Marvin H. Johnson, Jr. - Director
|
|
Peer Information
Trevena, Inc. (CORR.)
Trevena, Inc. (RSPI)
Trevena, Inc. (CGXP)
Trevena, Inc. (BGEN)
Trevena, Inc. (GTBP)
Trevena, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 89532E307
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/24
Next Expected EPS Date: 08/14/25
|
|
Share - Related Items
Shares Outstanding: 0.96
Most Recent Split Date: 8.00 (0.04:1)
Beta: 0.61
Market Capitalization: $0.95 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $ |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/14/25 |
|
|
|
| |
